Payment overview · 2025
General Payments
$1,199.70
11 reported records · 4 companies
Healthcare provider profile · identity verified
Krishna Kant Dixit, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEWBURGH, NY · NPI 1437239068
Verified facts
What the public records show
CMS Open Payments records show Krishna Kant Dixit, MD received $1,199.70 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 75.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $899.83 | 75.0% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $125.00 | 10.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.97 | 10.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $49.90 | 4.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,199.70 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $899.83 | 7 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $49.90 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 122 |
| Eliquis | Apixaban | 616 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 423 | 52 |
| Gabapentin | Gabapentin | 417 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 63 |
| Furosemide | Furosemide | 285 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 53 |
| Lisinopril | Lisinopril | 271 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 35 |
| Mirtazapine | Mirtazapine | 207 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 36 |
| Potassium Chloride | Potassium Chloride | 172 | 24 |
| Sertraline Hcl | Sertraline Hcl | 168 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 16 |
| Losartan Potassium | Losartan Potassium | 157 | 26 |
| Warfarin Sodium | Warfarin Sodium | 156 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 152 | 22 |
| Carvedilol | Carvedilol | 145 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 128 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 24 |
| Levetiracetam | Levetiracetam | 108 | 14 |
| Finasteride | Finasteride | 103 | 12 |
| Simvastatin | Simvastatin | 97 | 12 |
| Januvia | Sitagliptin Phosphate | 93 | suppressed |
| Baclofen | Baclofen | 85 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 15 |
| Tramadol Hcl | Tramadol Hcl | 80 | 20 |
| Memantine Hcl | Memantine Hcl | 79 | suppressed |
| Metformin Hcl | Metformin Hcl | 79 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | suppressed |
| Spironolactone | Spironolactone | 76 | suppressed |
| Jardiance | Empagliflozin | 75 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 70 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 12 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Brilinta | Ticagrelor | 63 | suppressed |
| Allopurinol | Allopurinol | 62 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 61 | suppressed |
| Glimepiride | Glimepiride | 58 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Famotidine | Famotidine | 54 | 18 |
| Humalog | Insulin Lispro | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 51 | suppressed |
| Scopolamine | Scopolamine | 51 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Insulin Lispro | Insulin Lispro | 50 | suppressed |
| Procrit | Epoetin Alfa | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Omeprazole | Omeprazole | 47 | 17 |
| Risperidone | Risperidone | 46 | suppressed |
| Gemtesa | Vibegron | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 33 |
| Nyamyc | Nystatin | 42 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Prednisone | Prednisone | 41 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 37 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 19 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 15 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Atenolol | Atenolol | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Travoprost | Travoprost | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | 11 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 12 |
| Lidocaine | Lidocaine | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Cabergoline | Cabergoline | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | 11 |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,199.70 · 11 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, OFEV, TEZSPIRE, TZIELD | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error